
Zealand Pharma is not the only biotech company to take a candidate drug all the way to the market. Another Danish biotech company could now be going global with a new psoriasis drug.
Forward Pharma has recently secured 60 million kroner (USD 10.35 million) from existing investors to be used to bring the candidate drug FP 187 to international markets – initially aimed at psoriasis patients, it will also be used to treat sclerosis later on.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app